Multiple sclerosis imposes a significant burden not only on individuals but also on healthcare systems and economies worldwide. A comprehensive global analysis titled ‘Measuring what matters: bridging the gap between disability impact and economic burden in multiple sclerosis’ reveals the extent of this strain across seven high-income nations: the United States, France, Germany, Italy, Spain, Sweden, and the United Kingdom. Conducted by Economist Impact and supported by Sanofi, the study combines insights from 850 neurologists, a literature review, and economic modeling to assess how disability related to MS translates into financial costs. The authors emphasize that current clinical evaluations often overlook non-visible symptoms, leading to gaps in care and resource allocation. By refining measurement tools to reflect patients’ real-life experiences, policymakers and providers can develop more effective, person-focused strategies that account for both health outcomes and socioeconomic impacts.
— news from Managed Healthcare Executive
— News Original —
Global MS analysis links disability burden to rising economic strain
Multiple sclerosis (MS) is a severe, progressive autoimmune disease that takes a personal and economic toll. To address this, a new Economic Impact global report called ‘Measuring what matters: bridging the gap between disability impact and economic burden in multiple sclerosis’ calls for a global strategy focused on more comprehensive, patient-centered care. n nThe report, sponsored by Sanofi, consists of a survey of 850 neurologists, a research review, and an economic analysis of MS disease burden across the United States, France, Germany, Italy, Spain, Sweden and the United Kingdom. n n“What is measured shapes what is managed,” the researchers, including Gerard Dunleavy, Ph.D., health policy economist at Economic Impact, write in the report. “By evolving the assessment landscape to better reflect the daily reality of living with MS, Economist Impact hopes to help bridge the gap between clinical metrics and lived experience, ultimately ensuring that invisible symptoms are no longer unmeasured and unaddressed.”